Seres Therapeutics Inc (MCRB) Insider John G. Aunins Sells 14,279 Shares of Stock

Share on StockTwits

Seres Therapeutics Inc (NASDAQ:MCRB) insider John G. Aunins sold 14,279 shares of the stock in a transaction that occurred on Monday, October 15th. The stock was sold at an average price of $5.94, for a total value of $84,817.26. Following the sale, the insider now directly owns 103,811 shares of the company’s stock, valued at $616,637.34. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

MCRB opened at $6.71 on Wednesday. The company has a quick ratio of 2.76, a current ratio of 2.76 and a debt-to-equity ratio of -0.61. The company has a market capitalization of $309.64 million, a PE ratio of -3.04 and a beta of 0.56. Seres Therapeutics Inc has a 12 month low of $5.64 and a 12 month high of $11.35.

Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings results on Thursday, August 2nd. The biotechnology company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.01. The business had revenue of $4.61 million during the quarter, compared to analysts’ expectations of $5.22 million. Seres Therapeutics had a negative return on equity of 256.24% and a negative net margin of 264.31%. As a group, research analysts forecast that Seres Therapeutics Inc will post -2.45 EPS for the current fiscal year.

MCRB has been the subject of a number of recent research reports. ValuEngine raised Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, October 2nd. Zacks Investment Research raised Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 1st. BidaskClub raised Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, July 7th. Finally, Bank of America cut Seres Therapeutics from a “neutral” rating to an “underperform” rating in a research report on Friday, August 3rd.

Institutional investors and hedge funds have recently bought and sold shares of the company. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Seres Therapeutics in the 2nd quarter valued at approximately $117,000. Bank of America Corp DE lifted its holdings in shares of Seres Therapeutics by 175.0% in the 2nd quarter. Bank of America Corp DE now owns 36,489 shares of the biotechnology company’s stock valued at $314,000 after buying an additional 23,222 shares during the period. A.R.T. Advisors LLC lifted its holdings in shares of Seres Therapeutics by 141.3% in the 1st quarter. A.R.T. Advisors LLC now owns 45,952 shares of the biotechnology company’s stock valued at $337,000 after buying an additional 26,909 shares during the period. Chicago Equity Partners LLC acquired a new stake in shares of Seres Therapeutics in the 2nd quarter valued at approximately $415,000. Finally, Schwab Charles Investment Management Inc. lifted its holdings in shares of Seres Therapeutics by 18.8% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 117,255 shares of the biotechnology company’s stock valued at $1,009,000 after buying an additional 18,562 shares during the period. 78.04% of the stock is owned by institutional investors and hedge funds.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI).

Featured Article: Stock Split

Insider Buying and Selling by Quarter for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply